ライフサイエンスコーパス: allogeneic bone marrow transplant

1 day 0 in experimental parent C57BL/6-->CB6F1 allogeneic bone marrow transplant.

2 s leukemia (CML) after treatment with IFN or allogeneic bone marrow transplant.

3 2 in the lymphoid organs of recipients of an allogeneic bone marrow transplant.

4 Most patients requiring allogeneic bone marrow transplant (allo-BMT) do not have

5 Cytomegalovirus (CMV) infection following allogeneic bone marrow transplant (allo-BMT) is controll

6 erived short-chain fatty acids (SCFAs) after allogeneic bone marrow transplant (allo-BMT).

7 , and contribute to activation of APCs after allogeneic bone marrow transplant (alloBMT), we examined

8 Mice were given either syngeneic or allogeneic bone marrow transplants along with lung Pneum

9 ho achieved a complete remission received an allogeneic bone marrow transplant as consolidation.

10 mmation-associated multifactorial disease of allogeneic bone marrow transplant (BMT) -induced graft-v

11 he 34 mutation-negative patients received an allogeneic bone marrow transplant (BMT) in first complet

12 s-host disease (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models.

13 f chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-al

14 jor histocompatibility complex (MHC)-matched allogeneic bone marrow transplant (BMT) recipients and m

15 against AML challenge in both syngeneic and allogeneic bone marrow transplant (BMT) recipients at bo

16 Allogeneic bone marrow transplant (BMT) recipients have

17 TEC and associated T-cell deficiency seen in allogeneic bone marrow transplant (BMT) recipients.

18 sm and allograft tolerance in mice receiving allogeneic bone marrow transplant (BMT) with minimal con

19 tients with CML at various time points after allogeneic bone marrow transplant (BMT).

20 uring preconditioning of the recipient of an allogeneic bone marrow transplant (BMT).

21 y we demonstrated that SHIP(-/-) mice accept allogeneic bone marrow transplants (BMT) without signifi

22 p between CD34+ cell dose and recovery after allogeneic bone marrow transplants (BMT).

23 or-derived haemopoiesis in the recipients of allogeneic bone-marrow transplants (BMT) involves extens

24 Recipients of allogeneic bone marrow transplants (BMTs) who have relap

25 e found in KGF-/- recipients of syngeneic or allogeneic bone marrow transplant, but using KGF-/- mice

26 ologic defects that can be corrected with an allogeneic bone marrow transplant can theoretically also

27 termine whether specific subsets of cells in allogeneic bone marrow transplants can effectively treat

28 from a 29-year-old male who had received an allogeneic bone marrow transplant for acute lymphoblasti

29 A total of 2,055 recipients of allogeneic bone marrow transplants for chronic myelogeno

30 Allogeneic bone marrow transplant from an HLA-matched si

31 complete remission received T cell-depleted allogeneic bone marrow transplants from HLA-identical si

32 rstitial pneumonia after either syngeneic or allogeneic bone marrow transplant in mice.

33 iller cells can weakly resist engraftment of allogeneic bone marrow transplants in mice.

34 ampath-1M, have been utilized extensively in allogeneic bone marrow transplants in order to purge the

35 , almost 45 years after the first successful allogeneic bone marrow transplants, infection remains th

36 T cells present in an allogeneic bone marrow transplant may produce graft-vers

37 luciferase-expressing Tregs over time in an allogeneic bone marrow transplant model and demonstrated

38 val of luciferase-expressing CIK cells in an allogeneic bone marrow transplant model.

39 or all patients and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients.

40 We describe a necrotizing cerebritis in an allogeneic bone marrow transplant recipient caused by th

41 mycosis either had leukemia (n = 14) or were allogeneic bone marrow transplant recipients (n = 13).

42 Allogeneic bone marrow transplant recipients often exhib

43 ew murine model of posttransplant infection, allogeneic bone marrow transplant recipients were infect

44 the pathogenesis of herpesvirus pneumonia in allogeneic bone marrow transplant recipients, transplant

45 as to the potential clinical uses of FTY in allogeneic bone marrow transplant recipients.

46 leukocytes (PBLs), and whole blood (WB) from allogeneic bone marrow transplant recipients.

47 An unexpected finding was noted in allogeneic bone marrow transplant studies using IL-7 rec

48 Allogeneic bone marrow transplants were performed betwee